This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
by Zacks Equity Research
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
by Zacks Equity Research
The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.
Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication
by Zacks Equity Research
Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).
The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $141.25, moving -0.63% from the previous trading session.
AstraZeneca to Supply 400M Coronavirus Vaccine Doses in Europe
by Zacks Equity Research
AstraZeneca's (AZN) supply deals will require it to produce 2 billion doses of the vaccine, if it is successfully developed.
Top Research Reports for Johnson & Johnson, Walmart & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Walmart (WMT) and Bank of America (BAC).
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain
by Sweta Jaiswal, FRM
Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) inks a deal with AstraZeneca to provide its CDMO services for supporting the manufacturing of the latter's COVID-19 vaccine candidate, AZD1222.
J&J to Begin Human Study on Coronavirus Vaccine in July
by Zacks Equity Research
J&J's (JNJ) goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.
Fed Sparks Economic Concerns: Winning Investment Strategies
by Sanghamitra Saha
The Fed now expects the U.S. unemployment rate to hit 9.3% this year and sees American GDP falling by 6.5% in 2020.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $146.77, marking a -0.36% move from the previous day.
AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment
by Zacks Equity Research
AbbVie (ABBV) collaborates with three parties for developing an antibody-based treatment for COVID-19.
J&J's Darzalex Subcutaneous Version Gets Approval in Europe
by Zacks Equity Research
J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.
AstraZeneca to Ensure Equal Access to Coronavirus Vaccine
by Zacks Equity Research
AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.
Novartis (NVS) Announces Positive Data From Cosentyx Study
by Zacks Equity Research
Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.
Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report
by Kinjel Shah
The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.
Novartis' sBLA for Ofatumumab Gets Extended Review From FDA
by Zacks Equity Research
The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JKF
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $148.25, marking a +0.72% move from the previous day.
Myovant Eyes Relugolix Combo Approval for Uterine Fibroids
by Zacks Equity Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy
by Zacks Equity Research
Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day